What this pack is
Wegovy is the brand name in this record; semaglutide is the generic name. Read both together with the dosage form (multiple forms (oral tablets and injectable product)).
PACK CHECK · MARKET FIRST
WegovyGeneric namesemaglutide
How this medicine works
The public DailyMed WEGOVY label describes semaglutide as a GLP-1 analogue and GLP-1 receptor agonist; GLP-1 is a physiological signal involved in appetite and energy-intake regulation. The label also describes delayed gastric emptying and glucose-dependent stimulation of insulin secretion with reduced glucagon secretion. This is a mechanism overview, not an answer to individual suitability, route, strength or frequency adjustment.
Read source: United States ↗reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- Wegovy
- Generic name
- semaglutide
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Subcutaneous injection / oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
A vial concentration, unit-per-mL value or device marking identifies the exact labelled product. It does not calculate an individual's amount, timing, administration, missed-use action, combination or switch.
WEGOVY single-dose prefilled syringes and oral tablets are separate labelled product identities. A shared brand or semaglutide ingredient, a milligram number, or a package image does not create an injection-to-tablet conversion, individual amount, schedule, combination or switch plan.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
10 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed public label (SPL v19, effective 18 Jun 2026); cited product identity only, not availability
0.25 mg/0.5 mL per single-dose prefilled syringe; carton of 4 syringes
- Product code
- NDC 0169-4525-14
- Form and route
- WEGOVY single-dose prefilled semaglutide syringe · subcutaneous (label product-identity field)
- Labelled concentration
- 0.25 mg/0.5 mL (labelled amount in the stated syringe; not an individual injection amount)Product identity, not an individual dose
- Container
- single-dose prefilled syringe · 0.5 mL
- Delivery device
- single-dose prefilled syringe
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-25; actual marketing, stock and availability are not established.
- semaglutide
- 0.25 mglabelled amount in one single-dose prefilled syringe; not an individual's injection amount, frequency, missed-use, conversion or switching instruction
- Package
- 4 × single-dose prefilled syringes per carton
United States label · Current U.S. DailyMed public label (SPL v19, effective 18 Jun 2026); cited product identity only, not availability
0.5 mg/0.5 mL per single-dose prefilled syringe; carton of 4 syringes
- Product code
- NDC 0169-4505-14
- Form and route
- WEGOVY single-dose prefilled semaglutide syringe · subcutaneous (label product-identity field)
- Labelled concentration
- 0.5 mg/0.5 mL (labelled amount in the stated syringe; not an individual injection amount)Product identity, not an individual dose
- Container
- single-dose prefilled syringe · 0.5 mL
- Delivery device
- single-dose prefilled syringe
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-25; actual marketing, stock and availability are not established.
- semaglutide
- 0.5 mglabelled amount in one single-dose prefilled syringe; not an individual's injection amount, frequency, missed-use, conversion or switching instruction
- Package
- 4 × single-dose prefilled syringes per carton
United States label · Current U.S. DailyMed public label (SPL v19, effective 18 Jun 2026); cited product identity only, not availability
1 mg/0.5 mL per single-dose prefilled syringe; carton of 4 syringes
- Product code
- NDC 0169-4501-14
- Form and route
- WEGOVY single-dose prefilled semaglutide syringe · subcutaneous (label product-identity field)
- Labelled concentration
- 1 mg/0.5 mL (labelled amount in the stated syringe; not an individual injection amount)Product identity, not an individual dose
- Container
- single-dose prefilled syringe · 0.5 mL
- Delivery device
- single-dose prefilled syringe
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-25; actual marketing, stock and availability are not established.
- semaglutide
- 1 mglabelled amount in one single-dose prefilled syringe; not an individual's injection amount, frequency, missed-use, conversion or switching instruction
- Package
- 4 × single-dose prefilled syringes per carton
United States label · Current U.S. DailyMed public label (SPL v19, effective 18 Jun 2026); cited product identity only, not availability
1.7 mg/0.75 mL per single-dose prefilled syringe; carton of 4 syringes
- Product code
- NDC 0169-4517-14
- Form and route
- WEGOVY single-dose prefilled semaglutide syringe · subcutaneous (label product-identity field)
- Labelled concentration
- 1.7 mg/0.75 mL (labelled amount in the stated syringe; not an individual injection amount)Product identity, not an individual dose
- Container
- single-dose prefilled syringe · 0.75 mL
- Delivery device
- single-dose prefilled syringe
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-25; actual marketing, stock and availability are not established.
- semaglutide
- 1.7 mglabelled amount in one single-dose prefilled syringe; not an individual's injection amount, frequency, missed-use, conversion or switching instruction
- Package
- 4 × single-dose prefilled syringes per carton
United States label · Current U.S. DailyMed public label (SPL v19, effective 18 Jun 2026); cited product identity only, not availability
2.4 mg/0.75 mL per single-dose prefilled syringe; carton of 4 syringes
- Product code
- NDC 0169-4524-14
- Form and route
- WEGOVY single-dose prefilled semaglutide syringe · subcutaneous (label product-identity field)
- Labelled concentration
- 2.4 mg/0.75 mL (labelled amount in the stated syringe; not an individual injection amount)Product identity, not an individual dose
- Container
- single-dose prefilled syringe · 0.75 mL
- Delivery device
- single-dose prefilled syringe
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-25; actual marketing, stock and availability are not established.
- semaglutide
- 2.4 mglabelled amount in one single-dose prefilled syringe; not an individual's injection amount, frequency, missed-use, conversion or switching instruction
- Package
- 4 × single-dose prefilled syringes per carton
United States label · Current U.S. DailyMed public label (SPL v19, effective 18 Jun 2026); cited product identity only, not availability
7.2 mg/0.75 mL per single-dose prefilled syringe; carton of 4 syringes
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 0169-4572-14
- Form and route
- WEGOVY single-dose prefilled semaglutide syringe · subcutaneous (label product-identity field)
- Labelled concentration
- 7.2 mg/0.75 mL (labelled amount in the stated syringe; not an individual injection amount)Product identity, not an individual dose
- Container
- single-dose prefilled syringe · 0.75 mL
- Delivery device
- single-dose prefilled syringe
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-25; actual marketing, stock and availability are not established.
- semaglutide
- 7.2 mglabelled amount in one single-dose prefilled syringe; not an individual's injection amount, frequency, missed-use, conversion or switching instruction
- Package
- 4 × single-dose prefilled syringes per carton
United States label · Current U.S. DailyMed public label (SPL v19, effective 18 Jun 2026); cited product identity only, not availability
Semaglutide 1.5 mg per tablet; 30-tablet bottle
- Product code
- NDC 0169-4415-31
- Form and route
- WEGOVY oral semaglutide tablet · oral (label product-identity field)
- Container
- plastic bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-25; actual marketing, stock and availability are not established.
- semaglutide
- 1.5 mglabelled amount per tablet; not an individual's tablet count, course, conversion or switching instruction
- Package
- 30 tablets per bottle
- Labelled appearance
- white to light yellow · round tablet; unscored · imprint 1.5 / novoUnscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v19, effective 18 Jun 2026); cited product identity only, not availability
Semaglutide 4 mg per tablet; 30-tablet bottle
- Product code
- NDC 0169-4404-31
- Form and route
- WEGOVY oral semaglutide tablet · oral (label product-identity field)
- Container
- plastic bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-25; actual marketing, stock and availability are not established.
- semaglutide
- 4 mglabelled amount per tablet; not an individual's tablet count, course, conversion or switching instruction
- Package
- 30 tablets per bottle
- Labelled appearance
- white to light yellow · round tablet; unscored · imprint 4 / novoUnscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v19, effective 18 Jun 2026); cited product identity only, not availability
Semaglutide 9 mg per tablet; 30-tablet bottle
- Product code
- NDC 0169-4409-31
- Form and route
- WEGOVY oral semaglutide tablet · oral (label product-identity field)
- Container
- plastic bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-25; actual marketing, stock and availability are not established.
- semaglutide
- 9 mglabelled amount per tablet; not an individual's tablet count, course, conversion or switching instruction
- Package
- 30 tablets per bottle
- Labelled appearance
- white to light yellow · round tablet; unscored · imprint 9 / novoUnscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v19, effective 18 Jun 2026); cited product identity only, not availability
Semaglutide 25 mg per tablet; 30-tablet bottle
- Product code
- NDC 0169-4425-31
- Form and route
- WEGOVY oral semaglutide tablet · oral (label product-identity field)
- Container
- plastic bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-25; actual marketing, stock and availability are not established.
- semaglutide
- 25 mglabelled amount per tablet; not an individual's tablet count, course, conversion or switching instruction
- Package
- 30 tablets per bottle
- Labelled appearance
- white to light yellow · oval tablet; unscored · imprint 25 / novoUnscored in this labelled presentation
PUBLIC LABEL IMAGE
Appearance and package-text clues
This dated or historical public-label image is for checking the brand, generic-name, strength and dosage-form clues only. It does not authenticate a product or establish originator status, a current label, current packaging, target-market approval or sale eligibility.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
WEGOVY label reading: the same name does not mean the same administration product
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses the current U.S. DailyMed public label as a reading entry point. It helps separate WEGOVY’s name, route, strength unit and package form; it does not provide an individual starting, escalation, missed-dose or substitution plan.
- Check “subcutaneous injection” or “oral”, the exact product strength, package form and target market together. Even with the same brand and generic name, different routes are not the same product to interchange by name, photo or total milligrams alone.
- For injection products, “mg/0.5 mL” or “mg/0.75 mL” contains both the medicine amount and liquid volume in the stated device; it is not an answer to how much anyone should inject. Milligrams on an oral tablet also require separate checking against that exact product’s current label, prescription and professional guidance.
- Pen, single-dose device, oral-tablet and different-strength package wording are product-identity clues, not instructions to independently change frequency, make up, combine, split or change to another semaglutide product.
- If other glucose-lowering medicines are used, dehydration or gastrointestinal symptoms occur, a procedure is planned, or an injection/oral change is being considered, bring the complete medicine list and actual package to the prescribing team or pharmacist; do not infer individual suitability from a webpage.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. WEGOVY semaglutide injection and oral-tablet label (Novo Nordisk; SPL v19, effective 18 Jun 2026) ↗reviewed 2026-08-20
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-08-20FDA: WEGOVY 2025 U.S. label (NDA 215256; current label cross-checked against DailyMed SPL v19) ↗reviewed 2026-08-20
Reviewed official safety records
A dated record is not automatically a current alert. Read the named product, form, batch, market, date and source type before treating it as relevant.
- FDA Drug Safety Communication: related labelling change for Wegovy and other GLP-1 receptor agonists2026-01-13 · On 2026-01-13, FDA issued a Drug Safety Communication requesting removal of existing suicidal-ideation/behavior language from prescribing information for Wegovy (semaglutide), Saxenda and Zepbound; FDA said its comprehensive review did not identify an increased risk with GLP-1 receptor agonists. The communication describes a U.S. regulatory action and named products only. It does not replace the exact product, current target-market label or an individual mental-health assessment; new or worsening mood, behavior or self-harm thoughts require prompt local emergency or clinical support, not self-directed medicine changes.Primary-source record (open linked document) ↗reviewed 2026-08-22
Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Wegovy (semaglutide). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Wegovy is the brand in this record and semaglutide is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg/mL, mg per vial or a total volume describes the labelled concentration or pack identity of an injectable product. It is not an individual infusion amount, preparation instruction or schedule.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a severe reaction, fainting, difficulty breathing or sudden worsening symptoms around an injection or infusion, use the local treatment team or emergency service now. Do not wait for a website reply or alter preparation, infusion or another medicine yourself.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When OZEMPIC / semaglutide injection is on the same list: products containing semaglutide need a complete medicine-list review
The current U.S. DailyMed WEGOVY public label states in Limitations of Use that concomitant use of WEGOVY injection or tablets with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended. This source-bounded cue means that every actual pack, dosage form, strength, prescription, OTC product and supplement should first be reviewed by a pharmacist or prescriber; it does not decide an individual's co-use or advise self-stopping, time-separation, replacement or adjustment of either medicine.
Open the Ozempic / semaglutide record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗reviewed 2026-08-20CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When RYBELSUS / oral semaglutide tablets is on the same list: products containing semaglutide need a complete medicine-list review
The current U.S. DailyMed WEGOVY public label states in Limitations of Use that concomitant use of WEGOVY injection or tablets with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended. This source-bounded cue means that every actual pack, dosage form, strength, prescription, OTC product and supplement should first be reviewed by a pharmacist or prescriber; it does not decide an individual's co-use or advise self-stopping, time-separation, replacement or adjustment of either medicine.
Open the Rybelsus / oral semaglutide record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗reviewed 2026-08-20HOW IT WORKS · NOT A TREATMENT PLAN
How semaglutide works: it activates the GLP-1 receptor and participates in appetite and energy-intake regulation
- “Affects appetite” cannot be read as everyone should use the product, should eat a certain amount less, or may self-increase it. Weight, gastrointestinal effects, nutrition intake, coexisting conditions and every medicine need the current label, prescription and professional assessment for the exact product.
- The label's “delays gastric emptying” is one clue for why oral co-medications need review; it cannot provide a self-made spacing schedule, stopping plan for oral medicines, equal conversion between injection and oral products, or a plan to add another GLP-1 product.
- Under the same generic name, prefilled pens, prefilled syringes, FlexTouch devices and oral tablets are different product-identity layers. Even with the same pharmacology, route, device, strength, target market and complete medicine list must be checked item by item; total milligrams do not permit self-substitution.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- FDA: WEGOVY 2025 U.S. label (NDA 215256; current label cross-checked against DailyMed SPL v19) ↗reviewed 2026-08-20
- DailyMed (NLM): current U.S. WEGOVY semaglutide injection and oral-tablet label (Novo Nordisk; SPL v19, effective 18 Jun 2026) ↗reviewed 2026-08-20
- FDA Drugs@FDA official search entry ↗Official lookup entry · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
Wegovysemaglutide
This page links to public primary-source material for Wegovy. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Dated current U.S. public-label record
This page links the current U.S. public label dated SPL v19, effective 2026-06-18 as an enlarged-reading and item-by-item checking entry point. It does not replace same-day verification of approval, supply, indication, strength or individual use in the target market.
DailyMed (NLM): current U.S. WEGOVY semaglutide injection and oral-tablet label ↗
MARKET SCOPE
Market-record boundary
United States
Current public label linkedOnly the U.S. public label listed on this page is linked; no stock, sale-eligibility or other-market conclusion is inferred.
Mainland China, EU, Japan
Market record not establishedNo local approval, holder, strength, supply or sale-eligibility conclusion is inferred from the U.S. public label.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Does a current U.S. label represent another country or region?
No. It is an item-by-item reading entry point; brand, dosage form, strength, availability and safety information still require checking against the target market's current official document.
Why are price and originator/generic conclusions not shown?
Those conclusions require separately complete and human-reviewed product, dosage-form, strength, pack, market, date and primary-record fields; one label file is insufficient.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.